Title : (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.

Pub. Date : 2019 Feb 15

PMID : 30781364






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lapatinib (LP) is an FDA-approved dual EGFR/HER2 inhibitor for HER2-amplified breast cancer. Lapatinib epidermal growth factor receptor Homo sapiens
2 Lapatinib (LP) is an FDA-approved dual EGFR/HER2 inhibitor for HER2-amplified breast cancer. Lapatinib epidermal growth factor receptor Homo sapiens
3 Antibody array and Western blot analysis showed that combined OC-LP treatment significantly inhibited EGFR, HER2, and c-Met receptor activation, as well as multiple downstream signaling proteins, compared to individual OC or LP treatment. Lapatinib epidermal growth factor receptor Homo sapiens